Compare CVS Health Corp (CVS) vs Oatly Group AB - ADR (OTLY) Price & Performance

CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.

The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.

Oatly (OTLY) trades at $10.00, up 1.52% today, showing modest momentum despite ongoing financial challenges. The company maintains a low P/S ratio of 0.35 but suffers from negative profitability metrics including a -17.06% net income margin and -245.57% ROE. Recent Q1 2026 earnings beat expectations with a smaller loss than projected, while technical indicators show mixed signals with an overall bullish bias. Cash flow remains negative but has improved from previous years, with operating cash burn narrowing to -$24 million in 2025.

Oatly faces significant execution risks with persistent losses and high debt levels (66.53% debt-to-asset ratio), though revenue growth continues and cash burn shows improvement. Analyst sentiment is divided with 44% buy ratings but 50% hold recommendations, reflecting cautious optimism about the company's turnaround potential amid competitive pressures in the plant-based beverage market.